J.P. Morgan Life Sciences Private Capital Welcomes Bruce N. Rogers, Ph.D. as Venture Partner

Rhea-AI Summary

J.P. Morgan (NYSE:JPM) Life Sciences Private Capital appointed Bruce N. Rogers, Ph.D. as Venture Partner. He is expected to use his experience in medicinal chemistry, translational science, neuroscience and immunology to help develop and scale portfolio companies within the life sciences investment platform.

Dr. Rogers is President and CEO of a precision immunology portfolio company of Life Sciences Private Capital and previously served as President of Morphic Therapeutic, where he built the integrin platform and asset portfolio, including MORF-057. Following Morphic’s $3.2 billion acquisition by Eli Lilly in 2024, he became Senior Vice President and CEO of Morphic at Lilly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Aug. 18, 2026 /PRNewswire/ -- J.P. Morgan Life Sciences Private Capital, the life sciences venture and growth equity arm within J.P. Morgan Asset Management, today announced the appointment of Bruce N. Rogers, Ph.D., as Venture Partner. Dr. Rogers will leverage his extensive background in medicinal chemistry, translational science, neuroscience, and immunology to develop and scale innovative companies with Life Sciences Private Capital.

Dr. Rogers is a seasoned drug discovery and development expert with a strong track record of building innovative companies that deliver therapies across biotechnology and the pharmaceutical industry. Dr. Rogers currently serves as President and CEO of an emerging precision immunology firm and a portfolio company of J.P. Morgan Life Sciences Private Capital.

Prior to that, Dr. Rogers was President of Morphic Therapeutic, where he originally joined as Chief Scientific Officer in 2016, built the company's platform, and delivered a portfolio of assets including MORF-057. Following Morphic's acquisition by Eli Lilly in 2024 for $3.2 billion, he transitioned to Eli Lilly as Senior Vice President and CEO of Morphic, overseeing the integration of Morphic's portfolio and team. Before his tenure at Morphic, Dr. Rogers served as Head of Neuro-Opportunities at Pfizer and spent 16 years within the medicinal chemistry divisions at Pfizer and Pharmacia, where he led teams that advanced over a dozen small molecule candidates into clinical trials across multiple neuroscience indications.

"Dr. Rogers has built a career that spans a diverse range of therapeutic areas and drug modalities, and that breadth of experience is a real asset to our team," said Dr. Stephen Squinto, CIO of Life Sciences Private Capital. "We look forward to working alongside him as we continue to grow our platform and support the next generation of life sciences companies."

Biography

Bruce N. Rogers, PhD, serves as President and CEO of an emerging precision immunology company focused on developing therapies that selectively target disease-driving T-cell populations. Previously, Dr. Rogers was President of Morphic Therapeutic, a biopharmaceutical company developing integrin therapies for serious chronic diseases, having initially joined the company as Chief Scientific Officer in 2016, building its platform and delivering a portfolio of assets including MORF-057. Following Morphic's acquisition by Lilly in 2024 for $3.2 billion, he transitioned to Lilly, where he held the roles of Senior Vice President and CEO of Morphic, overseeing the integration of Morphic's portfolio and team. Dr. Rogers brings deep experience in drug discovery and development, encompassing preclinical and clinical programs, medicinal chemistry, structural biology, translational science, DMPK, strategic partnering, and R&D planning. Before his tenure at Morphic, he served as Head of Neuro-Opportunities at Pfizer, leading innovative initiatives for central nervous system (CNS) disorders, including direct brain delivery of protein therapeutics for Parkinson's disease and oncology-oriented approaches. He also spent 16 years in progressively senior roles within the medicinal chemistry divisions at Pfizer and Pharmacia, leading teams that advanced over a dozen small molecule candidates into clinical trials for various neuroscience indications, such as tavapadon for Parkinson's disease and emraclidine for schizophrenia. Dr. Rogers has co-authored more than 60 scientific publications, reviews, and abstracts, and is credited as a co-inventor on over 85 patents and patent applications. He holds a BA in Chemistry from the University of Minnesota and a PhD in Organic Chemistry from the University of California, Irvine. Additionally, he was a National Institutes of Health postdoctoral fellow at the University of California prior to entering the pharmaceutical industry.

About J.P. Morgan Life Sciences Private Capital

J.P. Morgan Life Sciences Private Capital ("LSPC"), is the life sciences platform of J.P. Morgan Private Capital, the investment arm for private companies across the capital structure with a focus on venture and growth investing within J.P. Morgan Asset Management. LSPC partners with leading early-stage biotherapeutics and late-stage healthcare companies. The early stage biotechnology practice is focused on company creation, Seed and Series A investments across all therapeutic areas in biotechnology. The late-stage healthcare practice is focused on Series B through pre-IPO investments within biotechnology, medical devices, tools, diagnostics, healthcare technology and pharmaceutical services.

About J.P. Morgan Asset Management

J.P. Morgan Asset Management, with assets under management of $4.6 trillion as of June 30, 2026, is a global leader in investment management. J.P. Morgan Asset Management's clients include institutions, retail investors and high net worth individuals in every major market throughout the world. J.P. Morgan Asset Management offers global investment management in equities, fixed income, real estate, hedge funds, private equity and liquidity. For more information, visit: www.jpmorgan.com/am.

JPMorgan Chase & Co. (NYSE: JPM) is a leading financial services firm based in the United States of America ("U.S."), with operations worldwide. JPMorganChase had $5.0 trillion in assets and $375 billion in stockholders' equity as of June 30, 2026. The Firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing and asset management. Under the J.P. Morgan and Chase brands, the Firm serves millions of customers in the U.S., and many of the world's most prominent corporate, institutional and government clients globally. Information about JPMorgan Chase & Co. is available at www.jpmorganchase.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/jp-morgan-life-sciences-private-capital-welcomes-bruce-n-rogers-phd-as-venture-partner-302853620.html

SOURCE J.P. Morgan Asset Management

FAQ

Who is Bruce N. Rogers, Ph.D., appointed as Venture Partner at J.P. Morgan (JPM) Life Sciences Private Capital?

Bruce N. Rogers, Ph.D., is a drug discovery and development expert appointed Venture Partner at Life Sciences Private Capital. According to J.P. Morgan Life Sciences Private Capital, he brings extensive experience in medicinal chemistry, translational science, neuroscience, immunology, and company building across biotechnology and pharmaceutical sectors.

What will Bruce N. Rogers do as Venture Partner for J.P. Morgan (JPM) Life Sciences Private Capital?

As Venture Partner, Bruce N. Rogers will help develop and scale innovative life sciences companies within the Life Sciences Private Capital portfolio. According to J.P. Morgan Life Sciences Private Capital, he will leverage his scientific and leadership background to support venture and growth equity investments in biotechnology and pharmaceutical therapies.

What is Bruce N. Rogers’ background before joining J.P. Morgan (JPM) Life Sciences Private Capital?

Before joining as Venture Partner, Bruce N. Rogers served as President and CEO of a precision immunology company and previously led Morphic Therapeutic. According to J.P. Morgan Life Sciences Private Capital, he also held senior roles at Eli Lilly, Pfizer and Pharmacia in neuroscience-focused drug discovery.

How is Morphic Therapeutic’s $3.2 billion acquisition by Eli Lilly related to Bruce N. Rogers and J.P. Morgan (JPM)?

Bruce N. Rogers was President of Morphic Therapeutic when it was acquired by Eli Lilly for $3.2 billion in 2024. According to J.P. Morgan Life Sciences Private Capital, he then became Senior Vice President and CEO of Morphic at Lilly, overseeing portfolio and team integration.

What scientific and clinical experience does Bruce N. Rogers bring to J.P. Morgan (JPM) Life Sciences Private Capital?

Bruce N. Rogers brings experience spanning preclinical and clinical programs, medicinal chemistry, structural biology, translational science and DMPK. According to J.P. Morgan Life Sciences Private Capital, he has led teams advancing over a dozen small-molecule candidates into clinical trials for neuroscience indications like Parkinson’s disease and schizophrenia.

What are Bruce N. Rogers’ academic credentials as highlighted by J.P. Morgan (JPM) Life Sciences Private Capital?

Bruce N. Rogers holds a BA in Chemistry from the University of Minnesota and a PhD in Organic Chemistry from the University of California, Irvine. According to J.P. Morgan Life Sciences Private Capital, he also completed a National Institutes of Health postdoctoral fellowship before entering the pharmaceutical industry.